Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
- Written by PR Newswire Asia - News Pronto RSS
HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The preliminary data, with only a 10-month median follow-up,...